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conducted in Europe (5EU: France, Germany, Italy, Spain, and UK), Japan, US, Brazil, 
urban China, and Russia. Stratified random sampling based on sex and age (and 
ethnicity in the US) was used to ensure representativeness of the total regional 
adult populations. Quality of life (QOL) was assessed using the mental (MCS) and 
physical component summary (PCS) scores from the Short Form-12/36 (SF-12v2/
SF-36v2); work productivity loss was assessed using the Work Productivity And 
Impairment(WPAI) and health care resource use was self-reported. Descriptive 
analyses were conducted within each country; comparisons between developed and 
developing countries were made with respect to demographics, health history, and 
health outcomes. Results: The prevalence of PsO was 4.4% in 5EU, 1.0% in Japan 
and 2.4% in the US. The prevalence in developing countries was similar (Brazil 1.3%, 
Russia 2.1%, China 3.3%). Compared to those in developed countries, PsO patients 
in developing countries were more likely to be male, younger, married, employed, 
educated and have more comorbidities. Across both regions, PsO patients had lower 
scores in PCS & MCS, and higher activity impairment, work productivity loss, and 
health care resource use. The burden of PsO is associated with disease severity 
and BMI. All decrements exceeded cutoffs for clinical significance. ConClusions: 
Despite differences in patient demographics characteristics between developed and 
developing countries, significant burdens of PsO were observed across all countries 
with respect to worse QOL, higher health care resource use, and more work produc-
tivity loss than patients without PsO.
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objeCtives: The recent Institute of Medicine (IOM) workshop on “Hearing Loss 
and Healthy Aging” brought national attention to the broad health implications of 
untreated HL in older adults. The objective of this study is to explore the impact of 
HL on quality of life (QoL) on the US population, separate from the length of sur-
vival, using the 2000 Medical Expenditure Panel Survey (MEPS) and 2010 US Census 
data. Methods: Utility weights and population modeling using data from subjects 
age 60-90 from the MEPS 2000 sample were used to estimate utility decrements 
(UD), which were then applied to the 2010 US census population to estimate annual 
QALYs lost from chronic conditions for the US population. Results: Of the sam-
ple respondents 15.4% had mild (UD.034) and 1.1% had Moderate/Severe (UD.18) 
HL. Decrements due to joint pain 53% (UD.0643), hypertension 47.2% (UD.0292), 
diabetes 15.6% (UD.0577), angina 9.8% (UD.0352), asthma 7.9% (UD.0288), emphy-
sema 4.5% (UD.1186), and age (UD.0033) were calculated. When decrements were 
applied to the population the QALY loss ranged from 821,918 for joint pain 16,614 
for blindness. Contrary to HL’s low ranking in the Global Burden of Disease study, 
HL ranked 4th at 174,689 when survival is excluded and only older US patients are 
considered. ConClusions: HL has a substantial impact on healthy aging which is 
not obvious when QoL decrements include the effects on survival, or when younger 
people are included in the estimates. It is important to disassociate the effects of 
survival and the effects of a utility decrement when discussing the burden of ill-
ness for populations for whom QoL may be more important than length of survival. 
The results raises important issues for health policy formation for the aging “Baby 
Boomer” generation, indicating that the current lack of Medicare coverage for hear-
ing aids and related services should be reassessed.
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bACkgRound: While skin disease is one of the most common health problems in 
the United States, few studies have examined the impacts of medication use for 
common skin conditions on medication cost using national representative data, 
and much of these studies are out of date. objeCtives: To examine the impact of 
patient demographics and medication use on patient’ skin conditions specific medi-
cation cost, including acne, psoriasis, contact dermatitis, and rosacea. Methods: 
This retrospective cross-sectional study was conducted using data from the 2007 
Medical Expenditure Panel Survey (MEPS) database. Information on patient demo-
graphics, health status and medication use and cost were obtained representing 
a total of 4,429,674 patients with acne; 1,489,744 patients with psoriasis; 2,621,470 
patients with contact dermatitis and 1,214,775 patients with rosacea. Results: 
The weighted average annual total medication payments associated with specific 
conditions was about $183 for patients with acne; $3036 for patients with psoria-
sis; $62 for patients with contact dermatitis and $307 for patients with rosacea. 
Results of weighted multiple linear regression indicated that refill times of pre-
scribed medications were significantly related with higher medication expenditure 
for all of four skin conditions (prefill< 0.001). Being covered by private or public insur-
ance yielded an increase in medication expenditure except for psoriasis patients 
(acne: pprivate< 0.05, contact dermatitis: pprivate< 0.01, rosacea: pprivate< 0.01). Older 
adults with acne or contact dermatitis expended less on medication compared with 
younger adults (acne: page< 0.01, contact dermatitis: page< 0.05). ConClusions: By 
calculating the annual total medication expenditures, this study provides impor-
tant up-to-date information on the economic burden of these four common skin 
conditions. Results of this study indicated medication use and being covered by 
insurance were associated with medication expenditure. Expanding the coverage 
of insurance may increase medication spending for patients with skin conditions, 
thus impact of insurance coverage and medication use on patient health status 
needs further studies.
on a scale of 0 to 10. Relevance of pain to the patient experience with psoriasis 
was assessed using the patients’ descriptive language to identify related themes 
and assign codes to similar content. Resulting concept codes were evaluated for 
predominance (how much patients talked about each concept), severity, and being 
offered spontaneously. Results: The 30 subjects interviewed (CE, N= 20; CI, N= 10) 
were between 27 and 75 years of age (mean of 52), and were 30% female and 60% 
white. Concept codes for pain comprised 11% of all the expressions patients offered 
about their symptoms. Pain was the fourth most predominantly discussed symptom 
in the interview transcripts. In 11 of the 20 CE interviews subjects spontaneously 
offered pain as a symptom and rated its severity as 6.2 out of 10. ConClusions: 
These qualitative findings regarding the presence and severity of pain provide evi-
dence for the inclusion of pain as a key symptom concept of relevance to patients 
with moderate to severe psoriasis.
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objeCtives: To develop a patient-reported outcome (PRO) questionnaire meas-
uring symptoms, signs, and impact to assess treatment benefit in patients with 
moderate-severe plaque psoriasis(PsO). Methods: In-person 1:1 concept elicitation 
interviews were conducted to identify concepts relevant and important to moder-
ate-severe PsO patients (n = 20). An interview guide was designed to obtain input 
regarding symptoms, signs, impact on work, family and general well-being, and spe-
cific language to express issues related to having plaque PsO. Evidence of saturation 
was determined when no new concepts were mentioned. From these results, input 
from dermatologists, PRO experts, and published literature, a Psoriasis Symptoms, 
Signs and Impact Questionnaire (PSSIQ) was drafted. The PSSIQ was revised based 
on three waves of in-person cognitive debriefing interviews with moderate-severe 
plaque PsO patients (n = 19), and consideration of translatability into non-English 
languages. Results: The PSSIQ contains two sections. A Psoriasis Symptoms and 
Signs Diary (PSSD) includes 5 symptoms (itch, pain, stinging, burning, and skin 
tightness) and 6 patient observable signs (skin dryness, cracking, scaling, shedding 
or flaking, redness, and bleeding) using 0-10 numerical rating scales for severity. 
The second section, the Psoriasis Impact Questionnaire, includes items on impact 
of psoriasis on daily activities and emotional impact during the past 7 days. Two 
versions are available using a recall period of either the past 24 hours or past 7 days. 
Days with symptoms and signs experienced are collected in the 7-day version. 
During cognitive interviews, PsO patients found each item and the instructions in 
the questionnaire clear and relevant, and were able to provide a response with rela-
tive ease. ConClusions: The PSSIQ will be a valuable tool to evaluate treatment 
benefits of new therapeutic agents for patients with moderate-severe plaque PsO in 
clinical trials. Research examining its measurement properties, including reliability, 
validity, and ability to detect change, is underway.
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objeCtives: Vitreomacular adhesion (VMA) can lead to pathologic traction and 
macular hole formation. The effect of an intravitreal ocriplasmin-injection on VMA 
resolution was demonstrated in two multicentre, randomized, double-masked, 
phase 3 clinical trials (MIVI-TRUST). The objective of our analysis was to assess the 
effect of ocriplasmin on patient relevant visual function outcomes, measured using 
visual acuity (VA) and vision-related quality of life. Methods: Post-hoc analysis of 
prespecified secondary endpoints in MIVI-TRUST. A total of 652 participants with 
symptomatic VMA were enrolled, of whom 464 received a single intravitreal injec-
tion of 125µg ocriplasmin and 188 received a single intravitreal placebo-injection. 
Visual function response (VFR) was defined as either: a VA improvement of ≥ 2 lines; 
or an improvement exceeding the minimal clinically important difference (MCID) 
in the composite score of the National Eye Institute Visual Function Questionnaire 
(VFQ-25) or in the VFQ-25 driving subscale score. The MCID was estimated using 
the standard error of measurement approach. The main outcome measure was the 
VFR at 6 months. Results: The MCID was estimated at 3.6 points for the VFQ-25 
composite score and 19.1 for the VFQ-25 driving subscale score. A VFR occurred in 
55.1 % of the ocriplasmin-injection group versus 34.2% of the placebo-injection 
group (P< 0.0001). This comprised 23.7% versus 11.2% (P= 0.0003) with a ≥ 2 line 
VA improvement, 35.9% versus 22.7% (P= 0.0016) for the VFQ-25 composite score 
increase > MCID, and 10.2 % versus 6.2% (P= 0.1697) for the driving subscale score 
increase > MCID. ConClusions: Ocriplasmin produces significant and clinically 
meaningful visual function benefit to the patient in addition to higher VMA resolu-
tion rates. This analysis redefines visual function response and allows patient and 
physician to consider both anatomical and functional benefits when discussing 
treatment options.
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objeCtives: To evaluate the burden of psoriasis (PsO) in developed (Europe, US, 
and Japan) and developing countries (Brazil, China, and Russia). Methods: The 
analysis utilized data from the 2011 and 2012 National Health and Wellness Survey 
(NHWS, validated/stored by Kantar Health, USA) an annual cross-sectional survey 
